Wird geladen...
Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis
With 12 available US Food and Drug Administration approved medications for the treatment of relapsing multiple sclerosis (MS), choosing an initial therapy is no longer a straightforward task. Each disease-modifying therapy (DMT) has a distinct risk–benefit profile and each patient is an individual....
Gespeichert in:
| Veröffentlicht in: | Ther Adv Neurol Disord |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622114/ https://ncbi.nlm.nih.gov/pubmed/26557897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285615598910 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|